骨质疏松症的药物遗传学
Pharmacogenetics of osteoporosis.
作者信息
Marini Francesca, Brandi Maria Luisa
机构信息
Metabolic Bone Unit, Department of Internal Medicine, University of Florence Viale Pieraccini 6, 50139 Florence Italy.
出版信息
F1000 Biol Rep. 2010 Aug 19;2:63. doi: 10.3410/B2-63.
Abstract
Osteoporosis is a complex bone disorder with a strong genetic basis. The genetics of osteoporosis encompasses two main areas: genetics of disease susceptibility and pharmacogenetics of drug response. The former has been widely studied in the past few decades, while the latter is still largely untouched. This review will provide an overview of the pharmacogenetics of osteoporosis, focusing on the major recent advances in the past two years.
摘要
骨质疏松症是一种具有强大遗传基础的复杂骨骼疾病。骨质疏松症的遗传学涵盖两个主要领域：疾病易感性遗传学和药物反应药物遗传学。前者在过去几十年中已得到广泛研究，而后者在很大程度上仍未被触及。本综述将概述骨质疏松症的药物遗传学，重点关注过去两年中的主要最新进展。
相似文献
1
Pharmacogenetics of osteoporosis.
F1000 Biol Rep. 2010 Aug 19;2:63. doi: 10.3410/B2-63.
2
Pharmacogenetics of osteoporosis.
Expert Rev Endocrinol Metab. 2010 Nov;5(6):905-910. doi: 10.1586/eem.10.67.
3
Pharmacogenetics of osteoporosis: towards novel theranostics for personalized medicine?
OMICS. 2012 Dec;16(12):638-51. doi: 10.1089/omi.2011.0150.
4
Pharmacogenomics of osteoporosis: opportunities and challenges.
J Musculoskelet Neuronal Interact. 2006 Jan-Mar;6(1):62-72.
5
Pharmacogenetics of osteoporosis: future perspectives.
Calcif Tissue Int. 2009 May;84(5):337-47. doi: 10.1007/s00223-009-9226-x. Epub 2009 Mar 7.
6
Genetics and pharmacogenetics of osteoporosis.
J Endocrinol Invest. 2005;28(10 Suppl):2-7.
7
An overview of osteoporosis: from genetics to clinics.
Aging Clin Exp Res. 2011 Apr;23(2 Suppl):3-5.
8
The future of pharmacogenetics for osteoporosis.
Pharmacogenomics. 2013 Apr;14(6):641-53. doi: 10.2217/pgs.13.40.
9
Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy.
Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):481-8. doi: 10.1097/MED.0b013e32831a46be.
10
Pharmacogenetics of osteoporosis.
Best Pract Res Clin Endocrinol Metab. 2014 Dec;28(6):783-93. doi: 10.1016/j.beem.2014.07.004. Epub 2014 Aug 12.
引用本文的文献
1
Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study.
Genes (Basel). 2023 Feb 19;14(2):524. doi: 10.3390/genes14020524.
2
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.
Nat Rev Clin Oncol. 2013 Nov;10(11):625-42. doi: 10.1038/nrclinonc.2013.169. Epub 2013 Oct 1.
3
The influence of the genetic and non-genetic factors on bone mineral density and osteoporotic fractures in Chinese women.
Endocrine. 2013 Feb;43(1):127-35. doi: 10.1007/s12020-012-9726-8. Epub 2012 Jul 14.
本文引用的文献
1
Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women.
Yonsei Med J. 2010 Mar;51(2):231-8. doi: 10.3349/ymj.2010.51.2.231. Epub 2010 Feb 12.
2
LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
Calcif Tissue Int. 2009 Mar;84(3):171-9. doi: 10.1007/s00223-008-9207-5. Epub 2009 Jan 16.
3
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis.
Curr Med Res Opin. 2008 Sep;24(9):2609-15. doi: 10.1185/03007990802352894. Epub 2008 Aug 6.
4
Multiple genetic loci for bone mineral density and fractures.
N Engl J Med. 2008 May 29;358(22):2355-65. doi: 10.1056/NEJMoa0801197. Epub 2008 Apr 29.
5
Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism.
J Obstet Gynaecol Res. 2008 Feb;34(1):73-7. doi: 10.1111/j.1447-0756.2007.00680.x.
6
Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.
Clin Chem Lab Med. 2007;45(7):801-14. doi: 10.1515/CCLM.2007.184.
7
Pharmacogenomics of osteoporosis: opportunities and challenges.
J Musculoskelet Neuronal Interact. 2006 Jan-Mar;6(1):62-72.
8
Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen.
Maturitas. 2006 Mar 20;53(4):371-9. doi: 10.1016/j.maturitas.2005.07.007. Epub 2005 Aug 31.
9
Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women.
Hum Reprod. 2005 Jul;20(7):1860-6. doi: 10.1093/humrep/deh895. Epub 2005 Apr 14.
Zotero 插件